Biote Corp Stock Hits 52-Week Low at $3.65 Amid Market Challenges

Biote Corp (BTMD) shares tumbled to a 52-week low of $3.65, reflecting a challenging period for the company amidst a broader market downturn. Despite the price decline, the company maintains strong fundamentals with a 70% gross margin and positive earnings of $0.21 per share in the last twelve months. According to InvestingPro analysis, the company’s financial health score is rated as "GREAT." The stock’s significant decline over the past year, with a 1-year change showing a decrease of nearly 33.98%, has investors concerned about the company’s performance and future prospects. However, analysts maintain a bullish outlook, with price targets ranging from $8 to $12, suggesting significant potential upside. This latest price level represents a stark contrast to the stock’s previous momentum, as market participants reassess the company’s valuation and growth potential in the current economic climate. Management’s aggressive share buyback program and expected net income growth this year signal confidence in the company’s future. For deeper insights and additional ProTips about BTMD, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, BioTE Corp reported its fourth-quarter 2024 earnings, revealing a slight miss on earnings per share (EPS) forecasts. The company posted an EPS of $0.10, which fell short of the $0.11 forecast. Revenue also came in below expectations at $49.8 million, compared to the projected $51.29 million. Despite these results, BioTE demonstrated a year-over-year revenue growth of 9%, driven by a 5% increase in procedure revenue and a 10.2% rise in dietary supplement revenue. The company’s gross profit margin improved to 71.8%, up 247 basis points from the previous year. Additionally, BioTE has set its 2025 revenue guidance between $200 million and $280 million, with an adjusted EBITDA forecast of $59 million to $64 million. On the analyst front, BioTE’s performance has not prompted any recent upgrades or downgrades from major firms. The company continues to focus on expanding its BioTRx wellness platform and increasing practitioner acquisition as part of its strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.